A single dose of Regeneron Pharma's antibody cocktail casirivimab and imdevimab (trade name Regen-Cov) reduced the risk of COVID-19 by 81.6% for up to eight months, according to a Phase 3 trial.
Novavax Inc's COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.
A Phase 3 clinical trial will explore a pool of up to seven drugs approved by FDA for other conditions – an approach called drug repurposing – and test their safety and effectiveness in treating mild to moderate COVID-19.
A new COVID-19 antibody assay was able to detect IgG and IgM antibodies to determine viable donor samples for therapeutic use and clinical trials.
Read More
A Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy used for COVID-19.
Read More
A COVID-19 clinical trial will test the effectiveness of fluvoxamine, an antidepressant currently used to treat obsessive-compulsive disorder, social anxiety disorder, and depression.
Read More
The PRECISIONS clinical trial will determine if N-Acetyl-cysteine (NAC) is an effective treatment in a subset of IPF patients who carry a particular genetic variant.
Read More
The Novavax vaccine is the fifth COVID-19 vaccine candidate to begin clinical trials, after Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson.
Read More
Carrimycin has become the world’s first synthetic biological drug treatment for severe COVID-19 to receive US FDA approval for Phase III trials, according to its developer, the Tonglian Group.
Read More
aTyr Pharma Inc has completed the target enrollment in its Phase 1b/2a clinical trial for ATYR1923 in patients with pulmonary sarcoidosis.
Read More
The NIAID is enrolling participants in its ACTT-4 clinical trial to assess the effectiveness of dexamethasone plus remdesivir, compared to baricitinib plus remdesivir.
Read More
Two randomized, placebo-controlled clinical trials funded by the NIH are expanding enrollment to further evaluate convalescent plasma for COVID-19.
Read More
Two Phase 3 studies of Merck’s investigational 15-valent pneumococcal conjugate vaccine met their primary immunogenicity objectives.
Read More
“A potentially unexplained illness” in a recipient of AstraZeneca’s COVID-19 vaccine candidate AZD1222 has halted the company’s phase 3 clinical trial, the AP reports.
Read More
A phase 3 study of inhaled molgramostim therapy found the drug resulted in greater improvements in pulmonary gas transfer and functional health status than placebo in patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Read More